A Randomized, Open-Label, Multicenter Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab.

Trial Profile

A Randomized, Open-Label, Multicenter Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Bortezomib (Primary) ; Rituximab (Primary) ; Fludarabine
  • Indications Follicular lymphoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 27 Jun 2012 Companies added in the association field as reported by EudraCT.
    • 21 Mar 2012 Planned number of patients changed from 110 to 120 as reported by European Clinical Trials Database.
    • 03 Mar 2012 This trial has been completed in Greece and Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top